FindTrial
Sign In

Aspirin placebo

DRUG6 trials

Sponsors

Columbia University, Bayer, Genentech, Inc., Icahn School of Medicine at Mount Sinai, Montreal Heart Institute

Conditions

AspirinCardiovascular DiseasesDiabete Type 2Moyamoya DiseaseMoyamoya SyndromePeripheral Artery DiseasePrevention & ControlRemote Ischemic Conditioning

Phase 3

Warfarin Versus Aspirin Recurrent Stroke Study
CompletedNCT00027066
Columbia UniversityStroke
Start: 1993-06-30End: 2001-11-30Target: 2206Updated: 2011-06-17
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
CompletedNCT01776424
BayerPrevention & Control
Start: 2013-02-28End: 2021-06-15Updated: 2022-11-28
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
TerminatedNCT02072226
Genentech, Inc.Stroke
Start: 2014-05-31End: 2017-03-22Updated: 2018-07-03
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
CompletedNCT02325466
Icahn School of Medicine at Mount SinaiPeripheral Artery Disease, Type 2 Diabetes
Start: 2015-04-30End: 2018-05-04Updated: 2022-03-21
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
RecruitingNCT05633810
Montreal Heart InstituteCardiovascular Diseases, Diabete Type 2
Start: 2022-12-21End: 2027-12-01Target: 10000Updated: 2026-03-10

Unknown Phase

Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
Not yet recruitingNCT07762547
Beijing Tiantan HospitalAspirin, Moyamoya Disease, Moyamoya Syndrome +1
Start: 2026-07-15End: 2030-02-28Target: 724Updated: 2026-08-13

Related Papers

Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials.
2025-06-09
Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches.
2024-10-02
Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
European Heart Journal Open2024-08-311 citations
Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches.
2024-07-144 citations
Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial.
2024-06-226 citations
The Effects of Pantoprazole on Kidney Outcomes
Journal of the American Society of Nephrology2024-04-119 citations
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
2023-12-286 citations
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.
2023-08-0110 citations
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
2023-01-147 citations
Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease
European Journal of Preventive Cardiology2022-11-2810 citations
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events
JAMA Network Open2022-11-2112 citations
Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines
Rational Pharmacotherapy in Cardiology2021-11-031 citations
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
2021-07-0131 citations
Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery
JAMA Cardiology2021-06-1662 citations
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
Heart2021-05-219 citations
Risk stratification of cardiovascular complications using CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHADS<sub>2</sub> scores in chronic atherosclerotic cardiovascular disease.
2021-05-035 citations
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
2021-02-0112 citations
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline
Stroke2020-09-2123 citations
Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis.
2020-07-10
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
Journal of the American College of Cardiology2020-06-0161 citations

20 more papers not shown